Skip to content

Proton Magnetic Resonance Spectroscopy of Normal Breast Tissues in Women Volunteers

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00155090
Enrollment
80
Registered
2005-09-12
Start date
2005-01-31
Completion date
2005-12-31
Last updated
2005-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Magnetic resonance imaging,, breast disease

Brief summary

Magnetic resonance spectroscopy (MRS) is a diagnostic technique in MRI that distinguishes various metabolites on the basis of their slightly different chemical shifts or resonance frequencies. The Proton is the most abundant nucleus in the body. We will try to establish the typical proton MRS pattern of normal women breasts to be a guideline for future further investigations.

Detailed description

There are few reports regarding proton MRS in normal female breasts. The fibroglandular tissues and fat are the two major gross components in the breast. The water content in the fibroglandular tissues is much higher than that in the fat. There is still no documented report discussing proton MRS in normal female breasts of premenopausal and postmenopausal women. Our study is to evaluate the proton MRS findings among normal premenopausal and postmenopausal women breasts, to find out if there are statistical differences on the main proton MRS patterns, water and lipid peak intensities and ratios between the two groups.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* women age ranged 30 years of age or older, with normal mammograms or ultrasound in recent 3 months

Exclusion criteria

* any women not fulfilling the inclusion criteria

Countries

Taiwan

Contacts

Primary ContactJane Wang, MD
hstjen@yahoo.com.tw886-2-23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026